Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluid administration Clear all
Completed Not applicable Interventional

Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery

NCT06011187
View directory record Official record
Conditions
Decision Support System, Outcome
Interventions
Routine care, AFM
Procedure · Device
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Other
Eligibility
18 Years and older
Enrollment
2,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 20, 2026, 7:43 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Acute Concussion and Melatonin

NCT04731974
View directory record Official record
Conditions
Concussion, Mild, Concussion, Brain, Pediatric ALL
Interventions
Melatonin 3 MG, Placebo
Drug · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep

NCT01073943
View directory record Official record
Conditions
Bowel Preparation
Interventions
PicoPrep, HalfLytely, bisacodyl
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Clearwater, Florida • Hollywood, Florida • Inverness, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Fluid Immersion Simulation (FIS) System Versus Air Fluidized Bed (AFB) System for Pressure Ulcers

NCT03522714
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Fluid Immersion Simulation System, Air Fluidized Bed System
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 20, 2026, 7:43 AM EDT
Recruiting Phase 3 Interventional

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
54
States / cities
Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 20, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT05347147
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Presendin, Placebo
Drug
Lead sponsor
Invex Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

NCT03938584
View directory record Official record
Conditions
Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 20, 2026, 7:43 AM EDT
Not yet recruiting Not applicable Interventional

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

NCT07541404
View directory record Official record
Conditions
Subdural Hematoma
Interventions
NeoCast Embolic System, Onyx LES, an FDA-Approved Commercial Liquid Embolic
Device
Lead sponsor
Arsenal Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Protocolized Care for Early Septic Shock

NCT00510835
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Not applicable Interventional

Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure

NCT02935946
View directory record Official record
Conditions
Deglutition Disorders, Respiratory Aspiration
Interventions
Cold Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
36 Weeks to 43 Weeks
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 20, 2026, 7:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727
View directory record Official record
Conditions
Glycogen Storage Disease
Interventions
mRNA-3745
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Early Phase 1 Interventional

Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy

NCT02811627
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
16 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 20, 2026, 7:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 20, 2026, 7:43 AM EDT
Recruiting Not applicable Interventional

Real-Time Levodopa Level Monitoring in Parkinson Disease

NCT04735627
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

NCT03280056
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration
Biological · Other
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

NCT00005086
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, methotrexate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

NCT04771390
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 1 Interventional

Burn Micronutrient Repletion Pilot Study

NCT00879723
View directory record Official record
Conditions
Burn
Interventions
Vitamin and Mineral supplementation
Dietary Supplement
Lead sponsor
Southern Illinois University
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 20, 2026, 7:43 AM EDT
Not listed Phase 2 Interventional

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

NCT01509911
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
TL-118, Gemcitabine
Drug
Lead sponsor
Tiltan Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 20, 2026, 7:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Insulin Sensitivity After Weight Loss

NCT00627484
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Gastric bypass, Gastric banding, Sleeve gastrectomy, Very low calorie diet
Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 20, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

NCT04304144
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 20, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 20, 2026, 7:43 AM EDT